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The total chemical synthesis of 361-residue Dpo4 DNA polymerase 
(including N-terminal His-tag) is an ambitious undertaking that pushes the limits 
of solid-phase peptide synthesis (SPPS).  In chemical protein synthesis projects, 
smaller peptide segments are synthesized using SPPS and these segments are 
ligated together via native chemical ligation (NCL) to produce a full-length 
protein.  NCL is a chemoselective reaction that requires a C-terminal thioester 
and an N-terminal Cys residue to ligate peptide segments.  These requirements 
pose a challenge to synthetic protein chemists because Cys residues are rare in 
most proteins and C-terminal thioester selection is crucial to the success of the 
project because some thioesters react quickly and efficiently while others are 
slow and produce very low yields.  A strategically placed mutation, usually to 
optimize ligation sites, can make an impossible chemical protein synthesis 
project possible.  However, mutations must be chosen carefully to minimize their 
impact on the activity of the protein.  
 In the case of Dpo4, we identified three positions where mutations would 
greatly simplify our chemical synthesis efforts.  In order to safely make mutations, 
we used BLAST searches and crystal structure analysis to determine candidate 
residues.  We recombinantly expressed mutated Dpo4 constructs and compared 
their activity against wild-type Dpo4.  In this manuscript, we discuss the selection 
of the three mutated positions and the development of a PCR assay that allowed
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us to quantify differences in thermostability between mutant Dpo4 constructs and 
wild-type Dpo4.  This research highlights the importance of strategically placed 
mutations in chemical protein synthesis projects and also has the potential to 
impact the biotechnology field with the introduction of mirror-image PCR using 
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History of Chemical Peptide Synthesis 
Chemical peptide synthesis has a long and storied history stretching back 
to the early 1880s when Theodor Curtius successfully prepared an N-protected 
dipeptide benzoylglycylglycine.  This dipeptide was prepared by treating the silver 
salt of glycine with benzoylchloride.  The azide-coupling method discovered by 
Curtius and an acylchloride coupling method discovered by Emil Fischer were 
used for many years to chemically synthesize peptides.  However, these 
methods, employing carboxyl protecting groups, were limited by near complete 
racemization of the final product.  In contrast, an amino-protecting group, 
carboxybenzyl (Cbz), was developed by Max Bergmann (a former student of Emil 
Fischer) and Leonidas Zerwas, that increased the utility of peptide synthesis by 
greatly minimizing racemization (Kimmerlin 2005). 
 Until 1963, all peptide synthesis chemistry was done using solution-phase 
techniques that required each reaction to be isolated and purified before the 
addition of subsequent amino acids (Kimmerlin 2005).  Bruce Merrifield then 
pioneered a method known as solid-phase peptide synthesis (SPPS) in which 
each reaction is linked to an insoluble bead (Merrifield 1963) (Kimmerlin 2005).  
After each coupling reaction, the solid support can be washed to remove any 
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excess amino acid or coupling reagent, deprotected, washed again, and then 
coupled with the next amino acid.  Synthesis proceeds from C- to N-terminus, 
opposite from protein generation in a biological system.  Figure 1A shows Bruce 
Merrifield’s original synthesis scheme from his seminal paper in 1963, and Figure 
1B shows the general methodology used for SPPS. 
There have been many advances in the field of SPPS specifically relating 
to protecting groups and the chemistries involved in synthesizing peptides.  
Today, there are two main amino-protecting groups in use that differ in the 
chemistry involved to remove them to prepare for the next amino acid coupling 
step.  First, tert-butyloxycarbonyl (Boc) is an acid-labile amino-protecting group 
that requires the use of concentrated trifluoroacetic acid (TFA) for removal (Kent 
1988).  Second, fluorenylmethyloxycarbonyl (Fmoc) is a base-labile group that is 
removed upon treatment with piperidine (Carpino 1972).  In addition to these two 
main amino protecting groups, there are many other side chain protecting groups 
that prevent unwanted chemical reactions on side chains (Kimmerlin 2005).  The 
advent of SPPS greatly stimulated the field of peptide synthesis by making the 
process much faster and simpler, eventually allowing for automation (Kent 1988).   
In the Kay lab, we have chosen to use Fmoc SPPS because it is much 
safer than the Boc method.  Boc SPPS methods require treatment with TFA for 
every deprotection step and treatment with HF, an even harsher acid, for 
cleavage from the resin (Kent 1988).  We chose the Fmoc route to avoid dealing 
with pressurized TFA at every deprotection step. Fmoc SPPS only requires a 
small amount of TFA for cleavage from the resin at the end of the synthesis.  
Figure 2A shows the chemical structure of Fmoc-Cl, which is coupled to the 
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amino group of all twenty amino acids.  Figure 2B depicts the deprotection 
reaction that takes place upon treatment with piperidine.  After cleavage with 
TFA, which also removes the side chain protecting groups, the peptide is 
precipitated with ether and then purified using reverse-phase HPLC and analyzed 
using mass spectrometry.  
 
Chemical Synthesis of Proteins 
The study of proteins in biology has long been of interest both structurally 
and functionally.  The most common way of obtaining protein samples is by use 
of recombinant DNA techniques where a gene of interest is cloned into an 
expression plasmid that is introduced into an organism, mainly bacteria or yeast.  
The protein is then expressed and purified from the host cell.  Recombinant 
techniques work well for most proteins, but there are limitations such as the fact 
that some proteins are toxic or do not express well (Saida 2007).  Additionally, it 
is possible but very difficult to express unnatural amino acids in a recombinant 
system (Xie 2005).  
The major advantage of complete chemical synthesis of proteins is that 
the chemist has control over the chemical makeup of the protein.  This allows the 
incorporation of unnatural amino acids such as D-amino acids and fluorescent 
reporter groups (Kimmerlin 2005).  The limiting factors in chemical synthesis of 
peptides and proteins are the final yield and purity of the product.  Not every 
deprotection or coupling reaction is 100% efficient, leading to losses in yield and 
purity with each amino acid incorporation step (Kimmerlin 2005).  Due to 
decreasing yield with increasing peptide length, peptide synthesis is generally 
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limited to products of 50-70 amino acids long, though this limit is sequence 
dependent.   
In order to synthesize longer peptides or proteins, it is necessary to 
combine peptide segments synthesized via SPPS in a ligation reaction known as 
native chemical ligation (NCL).  NCL is a chemoselective reaction between a C-
terminal thioester and an N-terminal Cys (1,2-aminothiol), forming a native amide 
bond (Dawson 1994) (Johnson 2006) (Malins 2013) (Figure 3).  Since native Cys 
residues are not common in most proteins, synthetic peptide chemists have 
devised a way to use Ala residues as junctions for NCL.  The junction Ala residue 
is synthesized as a Cys residue and, after NCL has been completed, a free-
radical-based desulfurization reaction is employed which converts the Cys 
residue into an Ala residue (Dawson 2000) (Yan 2001).  Using Ala residues as 
NCL junctions greatly increases the number of potential junction sites, but also 
adds complexity to protein synthesis.  For example, if a native Cys residue needs 
to be maintained (rather than desulfurized) in the final protein, then it must be 
protected, typically with an acetamidomethyl (ACM) thiol-protecting group (Isidro-
Llobet 2008).  The ACM group then needs to be removed after the desulfurization 
reaction, a step that often results in significant loss of product (Harris 2007). 
A key factor that influences the rate and success of NCL is the C-terminal 
thioester residue.  Some residues complete the NCL reaction in less than 4 h, 
while others require more than 48 h (Hackeng 1999).  Thus, strategic selection of 
ligation sites in a protein synthesis project is a very important consideration that 




Kay Lab Goals 
 An important application of chemical protein synthesis is in preparing 
mirror-image D-peptides for use as therapeutics, and the Kay lab has long been 
focused on the use of D-peptides as viral entry inhibitors.  D-peptides are 
composed of D-amino acids and are mirror images of L-peptides (Figure 4).  
Unlike most small molecule inhibitors, peptides are capable of disrupting protein-
protein interactions otherwise considered “undruggable” targets.  The major 
disadvantage of peptide drugs is that they are rapidly broken down by proteases, 
hence requiring frequent and high dosing to be effective.  D-peptides are not 
broken down by L-proteases and therefore have a much longer half-life in the 
body (Weinstock 2012).  The Kay lab currently has a D-peptide HIV entry inhibitor 
that is in late preclinical trials (Francis 2012) (Welch 2010).  Some of the same 
methodologies that yielded success against HIV are now being applied to the 
development of a D-peptide Ebola entry inhibitor (Clinton 2014). 
Along with chemical synthesis of D-peptide therapeutics, we are also 
interested in engineering other ways to produce D-peptides and D-proteins, 
which would greatly simplify the process and also allow for large-scale 
production.  Our goal is to produce an in vitro translation system for the 
production of D-proteins by synthesizing all components of the ribosome and 
assembling them into a functional mirror-image ribosome.  With an assembled D-
ribosome it should be possible to produce D-proteins when the system is 
provided with mirror-image RNA, mirror image tRNA’s, mirror-image GTP and 
ATP (energy sources), and D-amino acids.  Such a mirror image in vitro 
translation system would be a great step forward for the routine production of 
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large D-proteins.  The long-term goal is to design a synthetic mirror-image 
organism that we have termed ‘D. coli’, which would be capable of producing D-
proteins in a large-scale format. 
 
DapA Review (Weinstock 2014) 
 
 With the chemical synthesis of larger D-proteins becoming feasible 
(though still very difficult), it is now necessary to take a step back and 
contemplate other difficulties that may arise when working with large D-proteins.  
In cells, there are multiple systems set up to assist folding proteins as they are 
translated by the ribosome.  Specifically, many larger proteins cannot fold into 
their active forms without the help of chaperones (Frydman 2001).   
The folding of large D-proteins is therefore an area of great interest if the 
field of D-protein synthesis is to advance to larger targets.  If L-chaperones are 
unable to fold D-proteins, then it would be necessary to synthesize and fold D-
chaperones, which would greatly complicate these already difficult projects.  With 
this in mind, the Kay lab set out to discover whether the E. coli GroEL/ES 
chaperone can fold a D-protein.  
 DapA (4-hydroxy-tetrahydrodipicolinate synthase) is an E. coli protein that 
relies upon GroEL/ES to fold into its active form (Kerner 2005).  DapA catalyzes a 
key step in lysine and diaminopimelic acid biosynthesis.  Interestingly, when 
GroEL/ES is not present, DapA is aggregated and degraded leading to cell death 
(Kerner 2005).  Based on these data, the Kay lab chose DapA as its first large D-
protein synthetic target. 
In order for this project to be successful, the 312-residue DapA protein 
	  	  
7	  
would have to be synthesized in D.  Then, both L- and D-DapA would be 
subjected to folding assays using L-GroEL/ES to determine the chaperone’s 
stereospecificity.  If correct folding was achieved, then functional assays could be 
performed to determine the activity of D-DapA compared to synthetic L-DapA and 
recombinant DapA. 
On the path to synthesizing the 312-residue DapA, the sequence was 
analyzed to find all Cys and Ala residues, as these could be used as ligation sites 
for NCL.  The protein was broken down into eight segments with each containing 
an N-terminal Cys or Ala.  This strategy required 12 handling steps (ligations, 
desulfurizations, and ACM removals) and proved impossible due to cumulative 
sample losses.  The assembly of the N-terminal half of the protein could be made 
much easier by eliminating the desulfurization reaction at the junction between 
segments 2 and 3.  Based on this idea, a BLAST search was done comparing the 
1,000 most-similar homologs of DapA, and it was found that 12% of these 
proteins had a Cys instead of an Ala at position 77.  Using this information as well 
as crystal structure analysis, it was decided that the synthesis should go forward 
using the A77C mutation to simplify the assembly.   
Another useful change to the synthesis strategy included combining 
segments 7 and 8 in the initial synthesis.  Combining other peptide segments was 
also pursued, but it was not possible to synthesize and purify these larger 
peptides with acceptable quality and yield.  These two changes, A77C and the 
combination of segments 7 and 8, removed four handling steps and their 
associated sample losses, enabling the successful assembly of the 312-residue 
DapA in both L- and D- forms.  Figure 5 shows the sequence of DapA along with 
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the synthesis strategy and Figure 6 shows the HPLC and mass spectrometry 
data obtained on the final L- and D-DapA synthetic products. 
Synthetic DapA was then subjected to folding experiments using 
GroEL/ES, and enzymatic activity assays were performed comparing 
recombinant wild-type protein to synthetic L and D-DapA.  Figure 7 shows that L-
GroEL/ES is able to refold D-DapA confirmed by activity assay normalized to 
recombinant DapA refolded by GroEL/ES. 
 The fact that GroEL/ES does not exhibit strict stereospecificity in folding its 
substrates is a major finding that has many implications for the future of D-protein 
synthesis. Given this result, many more D-protein targets are now potential 
candidates to be synthesized and further explored. 
 Using the knowledge that we gained from the DapA project, we are now 
attempting an even more ambitious synthetic protein project of the 352-residue 
DNA polymerase Dpo4.  We plan to synthesize this archeal DNA polymerase in 
both L- and D- forms and validate its function using PCR and extension assays.  

















Figure 1: Solid-Phase Peptide Synthesis.  (A) Bruce Merrifield’s original depiction 
of SPPS using a polystyrene bead from his seminal paper (Merrifield 1963).  (B) 
Diagram showing the process of SPPS.  The general cycle progresses from 
deprotection of the amino terminus, wash, amino acid activation, coupling 
reaction, wash, then deprotection and repeat.  When the synthesis is complete, 



























Figure 2:  Fmoc-Cl and Fmoc deprotection scheme.  (A) Chemical structure of 
Fmoc-Cl.  Fmoc-Cl is attached to the amino terminus of all amino acids and 
serves as a protecting group preventing unwanted couplings. (B) Piperidine-
catalyzed Fmoc deprotection of an amino acid on-resin.  This deprotection step 





























Figure 3:  Mechanism of native chemical ligation.  A reaction between a C-
terminal thioester and the thiol group of an N-terminal Cys residue occurs and 








































Figure 4:  Mirror-image peptide sequence.  (1) shows the sequence Asp-Val-Ser 
in L-form while (2) shows the same sequence in D-form.  They are mirror images 



























Figure 5:  Synthesis strategy for 312-residue DapA protein.  (A) Sequence of 
DapA with the N-terminal half denoted in green and the C-terminal half denoted 
in blue.  Ligation sites are underlined and shown in red.  (B) Successful synthetic 
strategy of DapA following the same coloring scheme as above.  Image from 











Figure 6:  Analysis of DapA.  (A) Analytical reverse-phase HPLC traces of 
recombinant, synthetic L-, and synthetic D-DapA.  (B/C) Mass spec data obtained 
for synthetic L-DapA (B) and D-DapA (C).  Image from (Weinstock 2014). 	  	  	  
 
Figure 7:  Analysis of GroEL/ES-mediated refolding of synthetic and recombinant 
DapA.  Percent activity is normalized to recombinant (+ GroEL/ES).  Synthetic L 
is shown in red and synthetic D is shown in blue.  The open circles for all three 
samples observed at the bottom of the graph represent the refolding when 














Dpo4 (DNA polymerase IV) was discovered in thermophilic Archea in the 
genus Sulfolobus (Boudsocq 2001).  It is a member of the Y-family polymerases 
known for being low-fidelity polymerases (Wu 2011).  Y-family DNA polymerases 
are found throughout all kingdoms of life (Boudsocq 2004).  The main function of 
these polymerases is to help cells deal with DNA damage, as they are capable of 
performing translesion synthesis (Boudsocq 2004).  When DNA polymerases 
from other families encounter common types of DNA damage such as thymine-
dimers or abasic sites, they stall and are unable to continue synthesizing DNA 
(McDonald 2006).  Y-family polymerases, such as Dpo4, are able to rescue this 
process by synthesizing past these DNA lesions, allowing the stalled polymerase 
to complete its job.  Because of this translesion synthesis capability, Y-family 
polymerases are of particular interest for use in attempting to replicate damaged 
ancient DNA (McDonald 2006). 
 There are multiple crystal structures of Dpo4, and through structure 
analysis it is apparent that there are four distinct domains (little finger, finger, 
palm, and thumb) as shown in Figure 8.  In general, Y-family polymerases have 
been shown to have more flexible active sites that are more solvent accessible 
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than high-fidelity polymerases (Kirouac 2011).  It is thought that because Dpo4 
has a solvent-accessible active site, it is more permissive with dNTP 
incorporation.  This property would explain the higher error rate and the ability to 
perform translesion synthesis (Kirouac 2011).  Another interesting feature of 
Dpo4 is that it is highly selective for dNTPs over NTPs.  However, with a single 
mutation (Y12A), Dpo4 gains the ability to incorporate NTPs, thus becoming a 
crude RNA polymerase (Kirouac 2011).  The bulky tyrosine residue at position 12 
is thought to clash with the 2’OH group of NTPs, preventing NTP incorporation 
through a mechanism dubbed the “steric gate” (Kirouac 2011).   
We have chosen Dpo4 as a synthetic target for multiple reasons.  First, its 
size of 352 residues is attractive to us as synthetic protein chemists because it is 
the smallest thermostable DNA polymerase on record, but would still be the 
largest synthetic protein on record.  Most DNA polymerases are much larger and 
therefore outside of the range of current or near-future synthetic techniques.  For 
example, the common bacterial DNA Polymerase II has 783 residues (small for a 
DNA polymerase).  We also chose Dpo4 because of its ability to be both a DNA 
polymerase and a RNA polymerase with a single mutation at Y12A.  Finally, we 
plan to synthesize Dpo4 in both L- and D- forms in order to enable mirror-image 
PCR, which could be useful in searching for D-life and also as a key intermediate 











In order to synthesize Dpo4, a protein containing 361 residues (including 
N-terminal His-tag), it was necessary to carefully analyze the sequence in order 
to formulate a synthesis plan.  In the initial analysis, we identified potential 
ligation sites, Cys or Ala residues, and then selected the initial synthetic peptide 
segments. We also searched for any obvious mutations that would not harm the 
structure or function of Dpo4, but could greatly simplify the synthesis. 
Our original synthesis plan divided Dpo4 into nine peptide segments 
(ranging from 26 to 53 residues).  The number of starting peptide segments 
correlates to the number of handling steps (purifications, ligations, etc.) required 
to assemble the full-length protein.  Our initial plan using nine peptide segments 
required at least 17 handling steps.  Since each handling step results in a 
significant loss of material, we reduced the number of starting peptide segments 
from nine to six by synthesizing longer initial peptides.  Figure 9 provides details 
on the six initial peptides, while the supplementary material presents data 
demonstrating the ability to synthesize and purify these longer segments.  
 
Mutant Evaluation 
After initial scouting syntheses, purifications, and ligations, we found three 
positions where mutations would greatly simplify our chemical synthesis efforts.  
In order to make these mutations, careful analysis is needed to minimize the risk 
that these changes will harm polymerase activity.  When selecting candidate 
residues to mutate, we look at BLAST searches of homologous proteins to 
determine which residues are most common at the position of interest.  We also 
	  	  
18	  
look at multiple crystal structures to see if there is anything obvious in the 
structure that would tolerate or even favor specific mutations. 
After deciding on possible mutations, we expressed these mutated 
proteins.  We then performed activity testing on these mutants and compared 
them to wild-type protein to determine if these mutations had a negative impact 
on the function of Dpo4.  Our primary goal for the activity testing aspect of this 
project was to use a PCR reaction to validate the function of Dpo4.  However, we 
initially struggled to get PCR to work with our recombinant enzyme.  Knowing that 
PCR was our final goal, we designed a primer extension assay (see Methods) 
that allowed us to determine differences in thermostability between different 
mutants while we were troubleshooting the PCR assay.  Using this primer 
extension assay we were able to measure the functionality and thermostability of 
different mutants compared to wild-type enzyme by heating the enzymes at 





 There is only one naturally occurring Cys residue in Dpo4 (at position 31).  
In order to complete the synthesis with this Cys intact, it would need to be 
protected with an ACM group during desulfurization of non-native Cys residues. 
Unfortunately, we have found ACM removal to be a highly challenging procedure 
in long peptide intermediates, commonly resulting in >50% loss of product.  
Further, ACM removal is not always 100% complete, requiring HPLC separation 
of our 361-residue product +/- ACM (likely very difficult).  Two candidate residues 
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appealed to us for this mutation (Ser and Phe) based on BLAST searches and 
structural analysis.  These mutations were generated and expressed 
recombinantly, and then tested for their impact on the thermostability of Dpo4. 
 Figure 10 directly compares wild-type to C31S and C31F using our primer 
extension assay.  C31S is slightly more thermostable than C31F.  C31S was fully 
active after 15 min heat treatment at 83.8° C, while C31F was not.  C31S was not 
active after heat treatment at 85.4° C for 15 min, in contrast to wild-type, which 
survives heat treatment up to 86.3° C.  Based on these data, we selected C31S 
to pursue further, but we still were concerned about the loss of thermostability in 
C31S compared to wild-type.   
 
Ile 101 
 The ligation site between peptide segments 3 and 4 (see Figure 9) 
employs an Ile thioester based on the wild-type sequence.  Unfortunately, 
isoleucine residues are very slow in NCL reactions (Figure 12) (Hackeng 1999) 
and after multiple attempts at 20-24 hour ligations with extremely poor yield, we 
decided to mutate this position to increase the reactivity of the thioester.  Two 
potential changes that would provide the greatest benefit for the NCL reaction 
and are favorable via BLAST and structural analysis are Phe and Met.  We made 
both of these mutants and performed activity testing to determine their effect on 
the functionality and thermostability of Dpo4 (Figure 11). 
Figure 11 shows the primer extension results of our I101 mutants with 
I101M showing robust activity after heat treatment at up to 85.4° and reduced 
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activity after treatment at 86.3°.  I101M was more thermostable than I101F, and 
I101M appears to be only slightly less thermostable than wild-type. 
 
A155C 
 In our current synthesis strategy, the last step of the assembly requires 
desulfurization of Cys 155 to Ala.  If this final desulfurization reaction is not 100% 
complete, then an HPLC purification would be necessary and require the 
separation of 361-residue Dpo4 with Cys from Dpo4 with Ala at position 155. 
Given the size of Dpo4 (~42 kD), separating these products with such a subtle 
difference (32 daltons with minor change in hydrophobicity) will likely be 
impossible.  However, if we introduce the A155C mutation, we would shift the 
final step of the assembly to be a ligation reaction, which would result in a much 
easier final purification (resolving the complete protein from the N- and C-terminal 
halves).  We are currently in the process of making the A155C mutation and will 
perform the activity testing in the near future.  
 
PCR Activity Testing 
 
 As stated above, we initially tried to use our recombinant Dpo4 to perform 
PCR, but with little success.  However, after we developed an in-depth 
purification and refolding protocol (see Methods), we observed small amounts of 
PCR product.  With this new glimmer of hope, we spent a lot of time and effort 
optimizing this method and were eventually successful in creating a reproducible 
PCR assay (see Methods) that is more robust than our initial primer extension 
assay.  During the optimization of the PCR assay, we struggled to obtain 
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reproducible data and determined that the heat sensor on our thermocycler had 
been malfunctioning.  We tried many other PCR machines but were not able to 
set the lid temperature to less than 100° C, which proved to be a problem even 
though the heating block was set to the mid-80s for the denaturation step.  
Finally, we found a thermocycler in the Bass lab (Biorad C100 Touch Thermal 
Cycler) that had a fully customizable hot lid, and we were able to set the lid 
temperature to 70° C.  This PCR method utilizes the gradient function on the 
thermocycler to assess the thermostability of proteins during the denaturation 
step of PCR.  Figure 13 compares wild-type, C31S, and I101M at four different 
denaturation temperatures using a 15 or 5 s denaturation step at the listed 
temperatures.   
These results confirmed the previous primer extension data with C31S 
unable to tolerate 15 s denaturation at any of the measured temperatures.  
However, we were able to rescue some C31S function using a 5 s denaturation 
protocol, and we observed good product yield after denaturation at 84.9° C, but 
not at 86° C.  For reference, wild-type enzyme is fully active at 87.2° for both 5 
and 15 s denaturations.  I101M looks to be slightly less thermostable than wild-
type, confirming the results seen in primer extension assays, but when the 
denaturation time was decreased to 5 s, it performs similarly to wild-type. 
 Knowing that we had found conditions where C31S and I101M were 
capable of performing PCR, we wanted to see if the double mutant (C31S & 
I101M) was also capable of performing PCR under these same conditions 
(Figure 14).  Unfortunately the double mutant was unable to perform this PCR 
reaction.  Based on our previous primer extension and PCR data, we knew that 
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C31S was much less thermostable than I101M.  The inability of the double 
mutant to perform PCR is likely an additive effect of the two mutants, with C31S 
more of a contributing factor.  This disappointing result forced us to reconsider 
the C31S mutation.  Thus, we decided to generate a C31A construct, which was 
the next mutation on our list for C31.   
Since we have such a narrow window for PCR with our recombinant 
enzymes, we developed alternate strategies to make the PCR reaction more 
robust.  One of these ideas was to use a short linear template instead of a large 
plasmid template (7222 bp).  We designed primers to amplify a ~370bp region of 
this larger plasmid with roughly 50 bp of excess DNA on either side of our PCR 
primers.  Using this simplified template (sTemplate), we tested our wild-type 
recombinant enzyme against a commercial Dpo4 enzyme from New England 
Biolabs (NEB).  Surprisingly, our wild-type enzyme was incapable of PCR while 
the commercial enzyme showed a very robust product (Figure 15).  We 
hypothesized that the N-terminal His-tag on our construct may be interfering with 
our recombinant enzyme’s performance and set out to design a construct with a 
TEV cleavage site for cleaving the His-tag after purification. 
 With two new constructs in hand (C31A and TEV-cleaved WT) we 
performed another round of activity testing.  First, we wanted to see whether 
C31A outperformed C31S in terms of thermostability.  Figure 16 confirms that 
C31A is the best option for mutation at this location as it performs the same as 
wild-type in this assay (5 s denaturation). 
We also wanted to test whether TEV-cleaved wild-type was capable of 
performing similarly to the commercial NEB enzyme (i.e. at higher temperatures 
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and the sTemplate reaction).  Figure 16 confirms that TEV-cleaved wild-type 
(denoted as NWT=naked wild-type) is a viable option moving forward, though this 
assay was not harsh enough to determine whether it performs similarly to the 
commercial enzyme. 
 We then decided to push the limits of our NWT enzyme by using higher 
temperatures for longer periods of time in the denaturation step and also to see 
whether NWT was capable of performing the sTemplate reaction.  Figure 17 
shows that NWT performs similarly to the commercial enzyme at higher 
temperatures for longer periods of time and that NWT is capable of performing 
the sTemplate PCR reaction.  Based on this result, we conclude that the N-
terminal His-tag hampers polymerase activity, thus we have found a solution to 
make our recombinant enzyme more robust. 
 
Conclusions and Future Directions 
 In conclusion, we have identified three mutants that will help with the 
synthesis of Dpo4 and have validated C31A and I101M individually using a PCR 
assay.  We also have discovered that the N-terminal His-tag that we have been 
using to purify our recombinant proteins and that also helps with the solubility of 
peptide segment 1-2 has a negative effect on the overall activity of the 
polymerase.  These results have led to a preliminarily revised Dpo4 synthesis 
plan, but there are still recombinant activity assay experiments that need to be 
performed before we can finalize our synthesis plan.  
First, we need to validate the double mutant C31A and I101M to confirm 
that these mutations do not impair the function of Dpo4 more than either of the 
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single mutants.  Next, we need to confirm that the A155C mutation does not 
greatly affect the performance of the polymerase.  We also need to validate that 
the proposed triple mutant (C31A, I101M, and A155C) is capable of performing 
PCR.  Based on the results of these activity assays, we will decide the fate of the 
His-tag in synthetic Dpo4.  If the double and triple mutants do not show robust 
activity with the His-tag and cleaving the tag increases their performance in PCR, 
then we will devise a synthesis plan that does not include the His-tag (either 
leave it out of the initial synthesis of peptide segment 1-2 or synthesize a TEV 
site that can be used to cleave the His-tag).  After validating the multimutants and 
determining the best course of action regarding the His-tag, we can proceed with 










Figure 8:  A ribbon diagram of Dpo4 in complex with DNA.  This structure shows 
the different domains (little finger, finger, palm, and thumb) and how they interact 









Figure 9:  Chemical synthesis of Dpo4.  (A) Target sequence for Dpo4.  Finger 
domain (blue), palm domain (red), thumb domain (green), and the little finger 
domain (purple) are shown.  Ligation sites are bold and underlined.  (B) Final 
synthetic strategy.  Peptide segments shown with the same color code as in A.  
Ligation thioesters and cysteine residues indicated on the initial peptides.  
Oxidation, native chemical ligation, ACM deprotection, and desulfurization steps 










Figure 10:  C31 mutants primer extension data.  C31 mutants compared to wild-
type.  The figure is labeled by the mutant and also the 15-min incubation 
temperature in C before performing the primer extension assay.  This assay 
allows us to see differences in thermostabilty compared to wild-type protein.  The 
brighter bottom band is the fully extended 90-mer duplex while the upper band is 
the single stranded 90 bp oligo paired with a 20-mer primer (not extended).  
C31S is slightly more thermostable than C31F, but it is concerning that both of 








Figure 11:  Primer extension data for I101 mutants.  Enzyme samples were 
heated to the indicated temperatures in C before performing the primer extension 
assay.  I101M is more thermostable than I101F.  I101M is only slightly less 
thermostable than wild-type Dpo4. 	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Figure 12: Kinetics of NCL reactions (different C-terminal thioesters).  All ligations 
were done using the sequences LYRAX-to-CRANK with X representing all 20 
amino acids shown in the graphs above.  This figure clearly shows the 
importance of wisely choosing C-terminal thioesters in synthetic protein assembly 









Figure 13:  PCR assay data for wild-type, C31S, and I101M constructs.  The top 
row underwent 15s denaturations at the listed temperatures while the bottom row 
underwent 5s denaturations at the same temperatures. (Top) Wild-type produces 
positive results at all shown temperatures.  C31S produces very faint bands at 
the two lower temperatures with no activity at the higher two temperatures.  
I101M is active up until 87.2°.  (Bottom) Wild-type and I101M perform similarly 
under the 5s denaturation conditions, and C31S yields robust results at the lower 








Figure 14:  PCR assay data for wild-type, C31S, I101M, and the double mutant 
C31S/I101M.  The three previously tested enzymes performed as expected, but 
the double mutant failed to produce positive results at any temperature. 	  	  	  
 
Figure 15:  PCR assay data (linear simplified template (sTemp)).  The 
commercial enzyme from New England Biolabs (NEB) produced very robust PCR 








Figure 16:  PCR assay data (C31A and TEV cleaved wild-type).  TEV cleaved 
wild-type denoted as NWT (naked wild-type).  C31A is capable of PCR at all of 
the listed temperatures and performs similarly to wild-type under the 5s 
denaturation protocol.  NWT also performs similarly to wild-type under these 








Figure 17:  PCR assay data comparing NWT to commercial NEB enzyme.  (Top) 
Higher temperatures for a longer period of time (15s).  NWT performs similarly to 
NEB and both of these enzymes out-perform His-tagged wild-type.  (Bottom) 
sTemplate reaction comparing His-tagged wild-type, NWT, and NEB.  NEB and 
NWT enzymes are capable of performing the sTemplate reaction while His-














Wild-type Dpo4 construct was cloned into pEXP5-CT vector used for T7-
based, high-level expression of recombinant proteins by our collaborators in the 
George Church lab at Harvard.  Mutants were made by quick-change or around-
the-horn PCR methodology.  Multimutant constructs were generated using 
restriction enzyme digests, gel purification, and ligation to yield double or triple 
mutants. 
 
Expression and Purification 
 
Dpo4 was expressed using BL21(DE3) pLysS competent cells in auto-
induction (ZY) media.  2 mL of 1 M MgSO4, 2 mL of 1000x metals mix, 2 mL of 
1000x Ampicillin stock, 40 mL of 50x 5052, and 100 mL of 20x NPS were added 
to 1.856 L of ZY media.  500 mL of media was aliquoted into 2.8 L baffled bottom 
flasks and each culture was inoculated using a single colony.  Cultures were 
grown at 37° C for ~16 h and harvested by centrifuge for 15 min at 5000 rpm 
(Beckman JLA-8.1000 rotor).  Cell pellets were sonicated in Ni Binding Buffer (20 
mM NaPO4 pH 8, 300 mM NaCl, 10 mM imidazole) with the addition of lysozyme.  
The sonicated material was then spun at 15,000 rpm (Thermo Scientific FiberLite 
F18-12x50 rotor) for 30 min to separate the soluble protein fraction from the 
	  	  
35	  
insoluble fraction.  The soluble fraction was adsorbed to Ni-NTA beads for 1 h 
and then eluted from the beads using elution buffer (20 mM NaPO4 pH 8, 300 
mM NaCl, 250 mM imidazole).  SDS-PAGE was used to confirm protein 
expression.  The eluted proteins were then dialyzed overnight at 4° C into storage 
buffer (50 mM Tris pH 8, 50 mM NaCl, 1 mM DTT), acidified using 5% AcOH to 
pH 3, HPLC purified on a Phenomenex C4 column (10 µ, 300 Å, 10 x 250 mm), 




Lyophilized Dpo4 powder was resuspended in denaturation buffer (6 M 
GuHCl, 50 mM Tris pH 8, 50 mM NaCl) to a concentration of ~25 µM in 1.5 mL 
final volume.  The unfolded protein solution was then dialyzed back into storage 
buffer (50 mM Tris pH 8, 50 mM NaCl, 1 mM DTT) using Thermo Scientific Slide-
a-Lyzer dialysis cassettes 3,500 MWCO overnight at room temperature in order 
to refold the protein.  Following refolding, the sample was then spun on a table-
top centrifuge at max speed for 10 min (to remove any particulates) and protein 
concentration was measured via A280 on a Biophotometer (extinction coefficient 
of 19,200 cm-1 M-1 and light scattering correction of A280corrected=A280-
(1.7*A320)).  This spun and refolded protein solution was used to perform activity 
assays described below. 
 




• Resuspend NEB-Lib-Extension and Ebo-fixed-SLLSA to a final 















Prepare Annealing Reaction 
• Add 2 µL of Ebo-fixed-SLLSA to a PCR tube 
• Add 4 µL of NEB-Lib-Extension to the PCR tube 
• Add 44 µL 1X TE to a final volume of 50 µL 
• Heat in thermocycler to 90 degrees for 5 min then turn machine off and let 
the annealing reactions cool slowly (~15min) 
 
 
Gradient Enzyme Preheat 
 
• Prepare 800 nM stocks of enzymes to be tested in NEB Thermopol buffer 
• Run the gradient program with enzyme samples in the appropriate lanes 
(ususally between 79 and 87 degrees for 15 min) 





• In 500uL eppendorf tubes, prepare the following for each reaction 
o 53 µL of ddH2O 
o 15 µL of 10x Thermopol buffer 
o 50 µL annealing rxn 
o 30 µL of 2.5mM dNTPs 
o 50 µL of gradient cooked 800nM enzyme 
• Incubate in thermocycler @60 degrees for 10 min then put rxns on ice 
• Negative control has no enzyme added and the excess volume made up 
with ddH2O 









Dpo4 PCR Protocol 
 
For each 25 µL reaction add: 
 
• 2.5 µL  Thermopol 10x buffer 
• 1 µL  Forward primer (10µM) M13 1470 
• 1 µL  Reverse primer (10µM)  -96 gIII sequencing primer from NEB 
• 1 µL  dNTPs (5mM) 
• 140 ng Template DNA M13KE plasmid 
• 2 µL  12.5µM recombinant enzyme or 2µL NEB enzyme diluted 6X 





M13 1470: cgcaactatcggtatcaagc 
-96 gIII: ccctcatagttagcgtaacg 
 
 
Prepare Annealing Reaction 
 
• Turn heat block on to 95° 
• Combine everything listed above (except enzyme) into an eppendorf tube 
labeled Master Mix   
o Prepare excess Master Mix to account for pipetting inaccuracies 
(e.g. to test 3 mutants at 4 temperatures, prepare enough for 15 
reactions) 
• Heat at 95° for ~3 min  
o Annealing reaction will become milky white due to the Triton X-100 
detergent present in the NEB Thermopol buffer 
• Remove the metal block from the machine and let cool to room 
temperature (20-30 min.)   





• Split annealing reaction into the same number of small eppendorf tubes as 
mutants that will be tested  
o For example: to test 3 enzymes at 4 temperatures, add 23x5=115 µl 
into 3 different tubes 
• Add enzyme to 1µM (2 µL of 12.5 µM enzyme per rxn)  
o Mix thouroughly 





Thermocycler Program (Gradient) 
 
 Biorad C1000 TouchThermal Cycler 
 
• Set Gradient for melt step at 84°-92° 
o Standard gradient: H=84°, G=84.9°, F=86°, and E=87.2° 
• Set lid to 70° 
 
Melt:  T=gradient 5 sec   
Anneal: T=56°  30 sec 
Extend: T=60°  1 min 
 25 Cycles 
Polish: T=60°  5 min 
Store:  T=4°  ∞ 
 
 
Agarose Gel Electrophoresis 
 
• Prepare a 1% agarose gel 
• Load 10 µL sample using Affymetrix 5X RapidRun Loading Dye 









The following figures contain RP-HPLC and mass spec data for all purified 
starting peptides.  (A) table showing calculated and observed mass for each 
peptide as well as the sequence and ions observed.  (B) RP-HPLC trace on C4-















	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




 Boudsocq F, Kokoska RJ, Plosky BS, Vaisman A, Ling H, et al. Investigating 
the role of the little finger domain of Y-family DNA polymerases in low 
fidelity synthesis and translesion replication. J Biol Chem. 2004 Jul 
30;279(31):32932-40. 
 
 Boudsocq F, Iwai S, Hanaoka F, Woodgate R. Sulfolobus solfataricus P2 DNA 
polymerase IV (Dpo4): an archaeal DinB-like DNA polymerase with lesion-
bypass properties akin to eukaryotic poleta. Nucleic Acids Res. 2001 Nov 
15;29(22):4607-16. 
 
 Carpino LA. 9-Fluorenylmethoxycarbonyl amino-protecting group. The   
  Journal of Organic Chemistry. 1972; 37(22):3404-3409. 
 
 Clinton TR, Weinstock MT, Jacobsen MT, Szabo-Fresnais N, Pandya MJ, et al. 
Design and characterization of ebolavirus GP prehairpin intermediate 
mimics as drug targets. Protein Sci. 2014 Oct 6. 
 
 Dawson PE, Muir TW, Clark-Lewis I, Kent SB. Synthesis of proteins by native 
chemical ligation. Science. 1994 Nov 4;266(5186):776-9. 
 
 Dawson PE, Kent SB. Synthesis of native proteins by chemical ligation. Annu 
Rev Biochem. 2000;69:923-60. 
 
 Francis JN, Redman JS, Eckert DM, Kay MS. Design of a modular tetrameric 
scaffold for the synthesis of membrane-localized D-peptide inhibitors of 
HIV-1 entry. Bioconjug Chem. 2012 Jun 20;23(6):1252-8.  
 
 Frydman J. Folding of newly translated proteins in vivo: the role of molecular 
chaperones. Annu Rev Biochem. 2001;70:603-47. 
 
 Harris KM, Flemer S Jr, Hondal RJ. Studies on deprotection of cysteine and 
selenocysteine side-chain protecting groups. J Pept Sci. 2007 
Feb;13(2):81-93. 
 
 Hackeng TM, Griffin JH, Dawson PE. Protein synthesis by native chemical 
ligation: expanded scope by using straightforward methodology. Proc Natl 





 Isidro-Llobet A, Alvarez M, Albericio F. Amino acid-protecting groups. Chem 
Rev. 2009 Jun;109(6):2455-504. 
 
 Johnson EC, Kent SB. Insights into the mechanism and catalysis of the native 
chemical ligation reaction. J Am Chem Soc. 2006 May 24;128(20):6640-6. 
 
 Kent SB. Chemical synthesis of peptides and proteins. Annu Rev Biochem. 
1988;57:957-89. 
 
 Kerner MJ, Naylor DJ, Ishihama Y, Maier T, Chang HC, et al. Proteome-wide 
analysis of chaperonin-dependent protein folding in Escherichia coli. Cell. 
2005 Jul 29;122(2):209-20. 
 
 Kimmerlin T, Seebach D. '100 years of peptide synthesis': ligation methods for 
peptide and protein synthesis with applications to beta-peptide 
assemblies. J Pept Res. 2005 Feb;65(2):229-60. 
 
 Kirouac KN, Suo Z, Ling H. Structural mechanism of ribonucleotide 
discrimination by a Y-family DNA polymerase. J Mol Biol. 2011 Apr 
1;407(3):382-90. 
 
 Malins LR, Mitchell NJ, Payne RJ. Peptide ligation chemistry at selenol amino 
acids. J Pept Sci. 2013 Nov 28. 
 
 Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. 
Journal of the American Chemical Society. 1963; 85(14):2149-2154. 
 
 McDonald JP, Hall A, Gasparutto D, Cadet J, Ballantyne J, et al. Novel 
thermostable Y-family polymerases: applications for the PCR amplification 
of damaged or ancient DNAs. Nucleic Acids Res. 2006;34(4):1102-11.  
 
 Saïda F. Overview on the expression of toxic gene products in Escherichia coli. 
Curr Protoc Protein Sci. 2007 Nov;Chapter 5:Unit 5.19. 
 
 Weinstock MT, Francis JN, Redman JS, Kay MS. Protease-resistant peptide 
design-empowering nature's fragile warriors against HIV. Biopolymers. 
2012;98(5):431-42. 
 
 Weinstock MT, Jacobsen MT, Kay MS. Synthesis and folding of a mirror-image 
enzyme reveals ambidextrous chaperone activity. Proc Natl Acad Sci U S 
A. 2014 Aug 12;111(32):11679-84. 
 
 Welch BD, Francis JN, Redman JS, Paul S, Weinstock MT, et al. Design of a 
potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J 





 Wu Y, Wilson RC, Pata JD. The Y-family DNA polymerase Dpo4 uses a 
template slippage mechanism to create single-base deletions. J Bacteriol. 
2011 May;193(10):2630-6. 
 
 Xie J, Schultz PG. Adding amino acids to the genetic repertoire. Curr Opin 
Chem Biol. 2005 Dec;9(6):548-54. 
 
 Yan LZ, Dawson PE. Synthesis of peptides and proteins without cysteine 
residues by native chemical ligation combined with desulfurization. J Am 
Chem Soc. 2001 Jan 31;123(4):526-33. 
 	  
